scholarly journals Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer

2013 ◽  
Vol 19 (20) ◽  
pp. 5788-5797 ◽  
Author(s):  
Wei Dai ◽  
Constanze Zeller ◽  
Nahal Masrour ◽  
Nadeem Siddiqui ◽  
James Paul ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Cpg Island ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Cancer Pathways ◽  
Cpg Island Methylation

scholarly journals Impact of humoral immune response against p53 on clinical outcome of High-Grade Serous Ovarian Cancer (HGSOC) patients

2016 ◽  
Vol 27 ◽  
pp. viii8
Author(s):  
M. Garziera ◽  
E. Cecchin ◽  
M. Montico ◽  
R. Roncato ◽  
S. Gagno ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Response ◽  
Clinical Outcome ◽  
Humoral Immune Response ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Humoral Immune

Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer

2016 ◽  
Vol 26 (4) ◽  
pp. 671-679 ◽  
Author(s):  
Hans-Christian Bösmüller ◽  
Philipp Wagner ◽  
Janet Kerstin Peper ◽  
Heiko Schuster ◽  
Deborah Lam Pham ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Clinical Outcome ◽  
Prognostic Value ◽  
Intraepithelial Lymphocytes ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Term Survival ◽  
Cell Counts

ObjectiveIncreased numbers of tumor-infiltrating lymphocytes (TILs) in high-grade serous ovarian cancer (HGSC) are associated with improved clinical outcome. Intraepithelial localization of TILs might be regulated by specific homing receptors, such as CD103, which is widely expressed by intraepithelial lymphocytes. Given the emerging role of CD103+ TILs, we aimed to assess their contribution to the prognostic value of immunoscoring in HGSC.MethodsThe density of intratumoral CD3+ and CD103+ lymphocytes was examined by immunohistochemistry on a tissue microarray of a series of 135 patients with advanced HGSC and correlated with CD4+, CD8+, CD56+, FoxP3+, and TCRγ+ T-cell counts, as well as E-cadherin staining and conventional prognostic parameters and clinical outcome.ResultsBoth the presence of CD103+ cells, as well as high numbers of intraepithelial CD3+ lymphocytes (CD3E), showed a significant correlation with overall survival, in the complete series, as well as in patients with optimal debulking and/or platinum sensitivity. Combining CD3 and CD103 counts improved prognostication and identified 3 major subgroups with respect to overall survival. The most pronounced effect was demonstrated for patients with optimally resected and platinum-sensitive tumors. Patients with CD3high/CD103high tumors showed a 5-year survival rate at 90%, CD3low/CD103high at 63%, and CD3low/CD103low at 0% (P < 0.001).ConclusionsThese results suggest that combined assessment of CD103 and CD3 counts improves the prognostic value of TIL counts in HGSC and might identify patients with early relapse or long-term survival based on the type and extent of the immune response.

scholarly journals Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor

2020 ◽  
Vol 37 (12) ◽  
pp. 5023-5031
Author(s):  
Isabelle Magalhaes ◽  
Josefin Fernebro ◽  
Sulaf Abd Own ◽  
Daria Glaessgen ◽  
Sara Corvigno ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Mesothelin Expression

scholarly journals Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Tomer Feigenberg ◽  
Blaise Clarke ◽  
Carl Virtanen ◽  
Anna Plotkin ◽  
Michelle Letarte ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Response ◽  
Clinical Outcome ◽  
Expression Profiles ◽  
High Volume ◽  
High Grade ◽  
Advanced Stage ◽  
Serous Ovarian Cancer ◽  
Immune Response Genes ◽  
Low Volume

Epithelial ovarian cancer consists of multiple histotypes differing in etiology and clinical course. The most prevalent histotype is high-grade serous ovarian cancer (HGSOC), which often presents at an advanced stage frequently accompanied with high-volume ascites. While some studies suggest that ascites is associated with poor clinical outcome, most reports have not differentiated between histological subtypes or tumor grade. We compared genome-wide gene expression profiles from a discovery cohort of ten patients diagnosed with stages III-IV HGSOC with high-volume ascites and nine patients with low-volume ascites. An upregulation of immune response genes was detected in tumors from patients presenting with low-volume ascites relative to those with high-volume ascites. Immunohistochemical studies performed on tissue microarrays confirmed higher expression of proteins encoded by immune response genes and increased tumorinfiltrating cells in tumors associated with low-volume ascites. Comparison of 149 advanced-stage HGSOC cases with differential ascites volume at time of primary surgery indicated low-volume ascites correlated with better surgical outcome and longer overall survival. These findings suggest that advanced stage HGSOC presenting with low-volume ascites reflects a unique subgroup of HGSOC, which is associated with upregulation of immune related genes, more abundant tumor infiltrating cells and better clinical outcomes.

Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17091-e17091
Author(s):  
Elena Ioana Braicu ◽  
Hagen Kulbe ◽  
Felix Dreher ◽  
Eliane T Taube ◽  
Frauke Ringel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Molecular Subtypes ◽  
Molecular Subtype ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Microarray Gene Expression ◽  
Tissue Samples ◽  
Paired Samples ◽  
Nanostring Technology

e17091 Background: Previously four molecular subtypes of high grade serous ovarian cancer (HGSOC) with distinct biological features and clinical outcome have been described: C1 (mesenchymal), C2 (immunoreactive), C4 (differentiated), and C5 (proliferative). Using Nanostring technique and a minimal signature of 39 classifier genes could reproduce the subtypes identified by microarray gene expression profiling (Leong HS et al. Australian Ovarian Cancer Study. J Pathol. 2015). Methods: We characterized paraffin embedded tissue samples from 279 HGSOC patients for molecular subtypes, utilizing the 39 classifier signature and 9 control genes by Nanostring nCounter Analysis System. From 16 patients paired primary and relapsed samples were available. Only chemonaive primary HGSOC patients were included in the study. FFPEs and clinical data were provided by TOC ( www.toc-network.de ). For each sample, probability scores for the four molecular subtypes (C1, C2, C4, and C5) were calculated. The highest calculated score determined the most likely subtype of the tumor. Results: Of all analyzed primary tumor samples, 88 (31.5%) were classified as C1, 83 (29.8%), 53 (19.0%) and 55 (19.7%) as subtypes C2, C4 and C5, respectively. Our results confirmed data by the AOCS study, which described the distribution of HGSOC with 40.2% (C1), 22.5% (C2), 20.1% (C4) and 17.2% (C5), respectively. Within the paired samples, for 12 of the 16 patients dynamic changes in the molecular subtypes between primary and relapse occurred, while in the remaining 4 patients the phenotype was stable. Conclusions: Molecular subtypes of HGSOC using Nanostring technology with a small panel of classifier genes can be confirmed. Furthermore, the data showed that a change of the established molecular subtype might occur during the evolution of the disease, and therefore translate in a different clinical outcome.

Abstract 5082: Determinants of clinical outcome in high grade serous ovarian cancer

2012 ◽  
Author(s):  
David D. L. Bowtell ◽  
Prue Cown ◽  
Dariush Etemadmoghadam ◽  
Kathryn Alsop ◽  
Joshy George ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
High Grade ◽  
Serous Ovarian Cancer

The clinical outcome of FAP+ cancer-associated fibroblasts in high-grade serous ovarian cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e17526-e17526
Author(s):  
Hanna Dahlstrand ◽  
Sara Corvigno ◽  
Artur Mezheyeuski ◽  
Joseph W Carlson ◽  
Josefin Fernebro ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Cancer Associated Fibroblasts ◽  
High Grade ◽  
Serous Ovarian Cancer

Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5579-5579
Author(s):  
Victoria Mandilaras ◽  
Stephanie Lheureux ◽  
Neda Stjepanovic ◽  
Julia Burnier ◽  
Michelle K. Wilson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Homologous Recombination ◽  
Clinical Outcome ◽  
Gene Mutations ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Recombination Gene
Sign in / Sign up

Export Citation Format

Share Document